All In Biotech

NDA 217651 · Baxter Hlthcare Corp

Cyclophosphamide

Cyclophosphamide · Intravenous

Last checked: Nov 20, 2026Latest source record: Jun 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jun 27, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

5,442

943 Phase 3, 897 recruiting

FAERS reports

179,391

172,655 serious, 36,268 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 10, 2024.

Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: • malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma • multiple myeloma • leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) • mycosis fungoides (advanced disease) • neuroblastoma (disseminated disease) • adenocarcinoma of the ovary • retinoblastoma • carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Cyclophosphamide Injection is an alkylating drug indicated for treatment of adult and pediatric patients with: • Malignant Diseases : malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1 )

Mechanism: The mechanism of action has not been fully characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cyclophosphamide interfere with the growth of susceptible rapidly proliferating malignant cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 27, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
2 products under this application
  • CYCLOPHOSPHAMIDE · CYCLOPHOSPHAMIDE 1GM/5ML (200MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • CYCLOPHOSPHAMIDE · CYCLOPHOSPHAMIDE 500MG/2.5ML (200MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclophosphamide" as an intervention, any sponsor and status, largest first.

All 5,442 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use16,826
  • febrile neutropenia14,787
  • drug ineffective10,788
  • neutropenia10,780
  • pyrexia9,368
  • disease progression8,229
  • pneumonia6,779
  • thrombocytopenia6,679
  • product use in unapproved indication6,563
  • nausea6,354
  • anaemia6,286
  • sepsis5,803

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,541
20051,760
20061,662
20071,990
20082,643
20093,104
20103,472
20115,665
20125,198
20133,764
20144,002
20155,802
20165,819
20177,870
201811,680
201912,218
202012,590
202112,754
202215,807
202317,132
202417,177
202515,538
202610,200

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cyclophosphamide* (Cyclophosphamide)

2024 spending

$2.1M

Beneficiaries

1,739

5,947 claims

Per beneficiary

$1,189

$74.34 per unit

View as table
YearSpending
2020$3,340,840
2021$2,857,636
2022$2,941,150
2023$2,681,596
2024$2,067,490

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9,013 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.